VBL Therapeutics won an ILS8.75 (approximately $2.5 million) grant from the Israel Innovation Authority to support continued clinical development of the firms lead Phase III-stage gene therapy ofranergene obadenovec (VB-111). The antiangiogenic candidate is being evaluated in a pivotal Phase III GLOBE study in patients with recurrent glioblastoma (rGBM) under an FDA Special Protocol Assessment. Phase II studies with VB-111 have previously been carried out in patients with platinum-resistant ovarian cancer and differentiated thyroid cancer indications.The gene therapy is administered as an IV infusion once every two months. <\/p>\n
VBL says the grant will fund clinical trials and development activities for the 2017 calendar year. The continuous financial support for the VB-111 program is an important contribution to our ability to execute on our plans into 2019, as we prepare for the commercialization of VB-111 and establish our new manufacturing site, commented Dror Harats, M.D., CEO at VBL Therapeutics. We believe this nondilutive grant for the VB-111 program underscores the confidence that the Innovation Authority has in our technology and its potential for commercialization. <\/p>\n
Vascular Biogenics Ltd., operating as VBL Therapeutics, is developing a portfolio of anticancer and anti-inflammatory programs based on its proprietary Vascular Targeting System (VTS) and lecinoxoidplatforms. VB-111 is an antiangiogenic, adenovirus 5 vector-based gene therapy developed using the VTS technology. <\/p>\n
VBL is, in addition, developing a series of orally available, small-molecule lecinoxoid compounds that exhibit immune modulating anti-inflammatory properties for treating chronic immune-related conditions. An exploratory Phase II study with lead lecinoxoid candidate VB-201 indicated that the compound reduces vascular inflammation in atherosclerosis. DuringApril, VBL separately presented data from a retrospective analysis of Phase II studies indicating that oral administration of VB-201 reduces levels of liver enzymes. The firm said the data support the potential use of lecinoxoids for liver-related indications, including nonalcoholic steatohepatitis (NASH). <\/p>\n<\/p>\n
<\/p>\n
Read more here: <\/p>\n
VBL Wins $2.5M Grant to Progress Pivotal-Stage Anticancer Gene Therapy - Genetic Engineering & Biotechnology News<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" VBL Therapeutics won an ILS8.75 (approximately $2.5 million) grant from the Israel Innovation Authority to support continued clinical development of the firms lead Phase III-stage gene therapy ofranergene obadenovec (VB-111). The antiangiogenic candidate is being evaluated in a pivotal Phase III GLOBE study in patients with recurrent glioblastoma (rGBM) under an FDA Special Protocol Assessment. Continue reading